It contributes to tissue inflammation in immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis [4]. Adalimumab is one of the TNF inhibitors. This evidence concerns the gene TNF and Crohn disease.